Abstract: The present invention is relates to a novel anhydrous dermatological depigmenting compositions comprising a phenolic compound, and methods of making and using the same.

Abstract: One aspect of the present invention relates to an effervescent tablet comprising a water-soluble lubricating agent, and a carbonated water cosmetic composition enabled to be used together therewith. One aspect of the present invention relates to an effervescent tablet comprising a crystalline #-hydroxy acid and a water-soluble lubricating agent, and a cosmetic composition using a skin toner for preventing the tablet from floating and allowing the tablet to rapidly form carbon dioxide gas in the cosmetic composition so as to maximize the visual effect and also the effect of carbon dioxide, thereby showing skin whitening, brightening and moisturizing effects and improving the pores.

Abstract: Suggested is a fragrance composition, comprising (a) at least one a fragrance selected from the group of aromatic nitriles according to formula (I) wherein R1, R2, R3, R4 and R5 independently of one another represent hydrogen or linear or branched C1-C10-alkyl, which is optionally substituted with hydroxy or C1-C4-alkyl or linear or branched C1-C10-alkoxy, which is optionally substituted with hydroxy or C1-C4-alkyl, and (b) at least one a solvent selected from the group consisting of benzylalcohol, benzylbenzoate, diethylphthalate, dipropylene glycol, ethyl alcohol, iso-propyl myristate, triethylcitrate, downol DPM, IsoPar L, triacetine and their mixtures.

Abstract: Disclosed are stable sunscreen compositions and corresponding methods for their use that are effective in protecting skin from UVA and UVB radiation. The composition uses a combination of ingredients to effectively and stably solubilize sunscreen agents to create a stable formulation.

Abstract: The invention is to provide a method for producing a soft capsule type external preparation (and a softening liquid (L) used for the production thereof, and an external preparation composed of such a capsule body (C)) which can be stably stored and leaves no film residues when rubbed with the finger when used as an external preparation although the external preparation is structured only as a capsule body (C) substantially having no external solution. An original capsule body (c) in which at least the external surface region inside an alginate capsule is present in the form of a polyvalent metal alginate is contacted with a softening liquid (L) composed of an aqueous solution comprising both “a basic amino acid (1)” and “an acid (2) selected from an organic acid or a phytic acid,” thereby impregnating the softening liquid (L) into the original capsule body (c) to obtain the capsule body (C).

Abstract: The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 ?m and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid.

Abstract: The present invention includes pyrimido[5,4-d]pyrimidines that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention.

Abstract: The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.

Abstract: Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable preservatives.

Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Abstract: The invention relates to compositions containing a) one or more substances selected from the group of hydrogen peroxide and substances releasing hydrogen peroxide, b) water, d) one or more substances selected from the group consisting of hydroxypyridones and the salts thereof, characterized in that said compositions do not comprise polymers having thickening properties. The compositions are particularly characterized by the advantageous storage stability thereof.

Abstract: The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.

Abstract: A composition of matter for treating sexual dysfunction is described, along with methods of making same, and methods of using same.

Abstract: A composite material having inherent microbicidal activity is herewith described. The microbicidal composite material comprises of a first layer having a first predefined thickness and a first predefined stitch/thread density; a second layer having a second predefined thickness and a second predefined stitch/thread density; an intermediate layer having a third predefined thickness and a third predefined stitch/thread density, wherein the intermediate layer is sandwiched between the first layer and the second layer, and where the intermediate layer is connected to the first layer and the second layer to form a three dimensional structure, and where each layer in the three dimensional structure has a plurality of apertures. Further, at least one layer in the three dimensional structure comprises at least one of microfibers and nanofibers having augmented surface moieties, wherein the augmented surface moieties allow for binding of a microbicidal agent to impart the inherent microbicidal activity.

Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Abstract: Novel compounds are disclosed having the structure of Formula I: wherein, n is an integer from 1 to 5; X is —CN, —F, —Cl, —Br, —I, —NO2; W is S, SO, SO2, O, NH, or NR5; R5 is alkyl, aralkyl, alkenyl, or alkynyl; Y is O, S; Z is NR1R2 or heterocycloalkyl; R1, R2 are, independently, hydrogen, alkyl, aralkyl, alkenyl, alkynyl, or cycloalkyl and may be optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, carboxy, alkoxycarbonyl, or nitrile groups; R3 and R4 are, independently, hydrogen, alkyl, aralkyl, alkenyl, alkynyl, or cycloalkyl and may be optionally substituted with halo, hydroxy, alkoxy, amino, alkylamino, carboxy, alkoxycarbonyl, or nitrile groups, and may together form a cyclic structure; and Ar is mono-, di-, or tri-substituted phenyl or heteroaryl, a pharmaceutically acceptable salts thereof. The compounds are potent bacterial efflux pump inhibitors (EPIs).

Abstract: A polymeric matrix for delivery of an HMG CoA reductase inhibitor such as a statin to tissue such as cardiac tissue in need thereof for the treatment or prevention of a disease or defect such as atrial fibrillation has been developed. In the preferred embodiment, a statin is delivered by means of a patch sutured to cardiac tissue at the time of cardiothoracic surgery. In the most preferred embodiment, the patch is a biodegradable material providing controlled or sustained release over a prolonged period of time, such as a week. Suitable materials include extracellular matrix, or other biodegradable hydrogels or polymeric materials providing sustained or controlled release of statin at the site of application.

Abstract: The present invention relates to a microcapsule particle composition that is composed of a sol-gel material. The microcapsule particle composition is well suited for personal care and cleaning products.

Abstract: The present invention relates to a method of cosmetic care that consists of applying, on at least one area of the body, a cosmetic composition containing an elastic mixture consisting of at least one starch, at least one polymer selected from polyvinyl alcohols, vinylpyrrolidone polymers and copolymers and latex, at least one polyol, and optionally water. The mixture imparts elasticity to the cosmetic product applied on the surface of the skin naturally subjected to deformations, such as the changes of facial expression, pressure of the fingers by contact, or contact with clothing.

Abstract: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents.